Although in situ hybridization has been used to examine the distribution of messenger RNA for somatostatin receptor subtypes (sst) in human tumors, the cellular localization of sst 1 and sst 2A receptors has not been reported. In this study, we describe the cellular localization of human sst 1 and sst 2A receptor proteins in both cryostat-and paraffin-embedded sections of 25 human tumor tissues using two recently developed polyclonal antibodies. Six somatostatin (SS) receptor (SSR) positive tumors (two gastrinomas, three carcinoids, one pheochromocytoma) and one SSR negative tumor (renal cell carcinoma), selected by positive and negative SSR autoradiography, respectively, were studied by both immunohistochemistry and Western blot analysis. The six SSR positive tumors expressed sst 2A , while 4 of 5 expressed sst 1 as well. The SSR negative tumor did not express either sst 1 or sst 2A . Western blot analysis of wheat germ agglutinin purified membrane proteins confirmed the presence of the sst 1 and sst 2A glycosylated receptors. The paraffin-embedded sections gave best information with respect to the subcellular localization. Sst 1 immunoreactivity was observed both on the membrane and in the cytoplasm, while sst 2A showed predominantly membrane-associated immunoreactivity. This subcellular distribution of sst 1 or sst 2A receptors was confirmed in paraffin-embedded sections of 8 additional intestinal carcinoids, 5 gastrinomas and 5 pheochromocytomas. Sst 1 receptors were detected in 7 out of 8 carcinoids, in all gastrinomas, and in 4 out of 5 pheochromocytomas, while 6 out of 8 carcinoids, all gastrinomas, and 3 out of 5 pheochromocytomas expressed sst 2A receptors. In conclusion, sst 1 and sst 2A receptors show a differential subcellular localization in human SSR positive tumors. The use of SSR subtype selective antibodies to detect the subcellular distribution of SSR subtypes in individual tumor cells is an important step forward to understand more about the pathophysiological role of the different SSR subtypes in human tumors. (J Clin Endocrinol Metab 84: 775-780, 1999) 
mation with respect to the subcellular localization. Sst 1 immunoreactivity was observed both on the membrane and in the cytoplasm, while sst 2A showed predominantly membrane-associated immunoreactivity. This subcellular distribution of sst 1 or sst 2A receptors was confirmed in paraffin-embedded sections of 8 additional intestinal carcinoids, 5 gastrinomas and 5 pheochromocytomas. Sst 1 receptors were detected in 7 out of 8 carcinoids, in all gastrinomas, and in 4 out of 5 pheochromocytomas, while 6 out of 8 carcinoids, all gastrinomas, and 3 out of 5 pheochromocytomas expressed sst 2A receptors. In conclusion, sst 1 A large number of human neuroendocrine tumors express somatostatin (SS) receptors (SSR) (1) . Five SSR subtype genes, named sst [1] [2] [3] [4] [5] have been identified and characterized (2) . Two isoforms of sst 2 (sst 2A and sst 2B ) are generated by alternative splicing. Until now, the detection of SSR in human tumors has been performed either by ligand binding to membrane homogenates or tissue slices to detect combined SSR binding activity, or by messenger RNA (mRNA) analysis using either in situ hybridization (ISH), RNAse protection, or reverse transcriptase polymerase chain reaction (RT-PCR) to detect mRNA for each receptor subtype. While the use of in vitro SSR autoradiography and ISH has provided significant information regarding the heterogeneity of SSR expressed in tumors (1, 3) , the precise cellular localization of SSR's has been difficult to establish. Recently, two SSR subtype specific polyclonal antibodies have been developed (4, 5) . The sst 1 antibody (code-named R1-201) was raised against a 15-amino acid peptide corresponding to a unique sequence in the carboxyl terminus and characterized by immunoprecipitation of photoaffinity-labeled sst 1 receptor (4). The sst 2A antibody (code-named R2-88) was raised against a 22-amino acid peptide located in the C-terminal region of the rat sst 2A receptor and characterized by immunopreciptation of photoaffinity labeled sst 2A receptor as well as by immunoblot and immunohistochemistry (IHC) on cells transfected with complementary DNA encoding sst 2A (5, 6) . The peptide sequences used to raise both antibodies are conserved in the rat, mouse, and human forms (4, 5) . The sst 2A antibody has recently been used to detect sst 2A in rat brain, pancreas, and pituitary sections (6 -8) . In this study we have used both antibodies to characterize the subcellular localization of sst 1 and sst 2A in human neuroendocrine tumors.
Materials and Methods

Tumor samples
Tumor tissue was obtained immediately after surgical removal and either frozen in liquid nitrogen through isopentane or fixed in 4% paraformaldehyde (PF) overnight. Diagnosis was made on the basis of clinical and biochemical characteristics of the patients, in combination with IHC of the tumor samples. All patients gave their informed consent for the use of tumor material for research purposes.
Immunohistochemistry
Frozen material. Five-micrometer cryostat sections were air-dried, fixed for 10 min with 10% PF, washed once with tap water, once with phos-phate buffered saline (PBS), and incubated for 15 min in normal goat serum (1:10 dilution in PBS ϩ 5% BSA). Thereafter, the sections were incubated overnight at 4 C with the sst 1 (R1-201) and sst 2A (R2-88) antibodies in a dilution of 1:1000. Finally, a standard streptavidin-biotinylated-peroxidase complex (ABC) kit (Biogenix, San Ramon, CA) was used according to the manufacturers instructions to visualize the bound antibodies.
Paraffin-embedded material. Five-micrometer sections were deparafinized, dehydrated, exposed to microwave heating (in citric acid buffer, 10 min at 100 C), rinsed in tap water (1x) and PBS (1x), and processed further as described above for the cryostat sections (sst 1 and 2A antibody dilutions: 1:500). Negative controls for IHC included omission of the primary antibody and preabsorbtion of the antibodies with the respective immunizing receptor peptides (at a concentration of 0.3 g/mL ϭ 100 nm).
Western blot analyis
Membranes were prepared from human tumors or cell lines transfected to overexpress either the rat sst 2A receptor (GH-R2) or the rat sst 1 receptor (GH-R1) (4 -6). Glycosylated proteins were purified by wheat germ agglutining (WGA) affinity chromatography as previously decribed (8) . Either unpurified or WGA-purified membrane proteins were subjected to electrophoresis on 12% SDS polyacrylamide gels and then transferred to polyvinylidene difluoride (PVDF) membranes electrophoretically (4 -6). After blocking, blots were incubated overnight at 4 C with 1:10,000 dilution of the appropiate antibody. Immunoblots were blocked, washed, and developed as described previously (5) (6) (7) (8) .
SSR autoradiography
SSR autoradiography was carried out as described previously (9) . Ten-micrometer sections were mounted onto precleaned gelatin coated microscope slides and stored at Ϫ80 C. To wash out endogenous somatostatin, the sections were preincubated at room temperature for 10 min in 170 mm Tris-HCl pH 7.4. Thereafter, the sections were incubated for 60 min at room temperature in 170 mm Tris-HCl pH 7. The incubated sections were washed twice for 5 min in incubation buffer containing 0.25% BSA and once in incubation buffer without BSA. After a short wash with distilled water to remove salt, the sections were air dried and exposed to Kodak X-OMAT AR or Hyperfilm TM -3 H (Amersham, Buckinghamshire, United Kingdom) for 3-7 days in x-ray cassettes. Histology was performed on hematoxylin-azophloxine stained sequential cryosections.
Results
Seven human neuroendocrine tumors of different origin were selected on the basis of positive and negative SSR autoradiography (Table 1 ). Figure 1 shows the localization of sst 1 (Fig 1, A, B , E) and sst 2A receptors (Fig. 1, C (Table 1) .
To enrich the tumor extracts for the glycosylated receptor proteins, solubilized membrane proteins were partially purified by WGA-affinity chromatography before immunoblotting. Figure 2 compares the results of the sst 1 and sst 2A analysis in a gastrinoma and an intestinal carcinoid to the staining observed in an SSR negative pituitary cell line (GH12C1) transfected to express either sst 1 and sst 2A . In each case, the most darkly stained band shows the broad migration pattern and size range characteristic of sst receptors. Immunostaining of this band was completely inhibited by 0.5-1 m antigen peptide (Fig. 2) . Data from all tumors examined are summarized in Table 1 . The apparent molecular weight (Mw) for each receptor subtype varied between tumors: the observed Mw for sst 1 ranged from 45 to 80 kDa, whereas that for sst 2A varied from 60 to 85 kDa. This variability is consistent with differential glycosylation occuring in individual tumors and resembles what was previously observed in tumor cell lines (4 -5) and rat tissues (6 -8) .
To further confirm the differential subcellular localization of sst 1 and sst 2A receptors in the tumor cells, we performed immunohistochemical analysis of both receptor subtypes in paraffin-embedded sections of eight additional intestinal carcinoids, five gastrinomas, and five pheochromocytomas. Sst 1 receptors were detected in seven out of eight carcinoids, in all gastrinomas (n ϭ 5), and in four out of five pheochromocytomas. Positive immunostaining for sst 2A receptors was found in 6 out of 8 carcinoids, in all gastrinomas (n ϭ 5), and in three out of five pheochromocytomas. This is shown in Table 2 . In all tumors specificity of the staining with the sst 1 -specific antibody (R1-201) and with the sst 2A -specific antibody (R2-88) was confirmed by the abolishment of immunostaining when the antibodies were pre-absorbed with 100 nm of the respective immunizing peptides. Figure 3 shows examples of the neutralization of the predominant cytoplasmic staining for sst 1 receptors in an intestinal carcinoid (Fig. 3, A, B) and in a gastrinoma (Fig. 3, C, D) , as well as for the predominant mem- brane-associated staining of sst 2A -receptors in a gastrinoma (Fig. 3, E, F) and a pheochromocytoma (Fig. 3, G, H) . In the tumors studied, irrespective of the tumor type, we confirmed the primarily cytoplasmic localization of sst 1 receptors and the preferential localization of sst 2A receptors at the cell membrane.
Discussion
Along with the widespread actions of SS, many SS-target tissues as well as many neuroendocrine tumors often originating in these target tissues, have been shown to express SSR's (1, 10) . Until now SSR detection has been performed using ligand binding studies on membrane preparations or on frozen sections. In addition, the recent cloning and characterization of the genes of five SSR subtypes (2) has provided molecular biological tools, i.e. RT-PCR and ISH techniques, to study SSR subtype expression in normal and tumoral tissues (3) . Moreover, the development of SSR subtype specific antibodies (4 -8) now allows a detailed study of the cell types and cellular localization of SSR subtype proteins. In the present study we describe the cellular localization of sst 1 and sst 2A receptors in human neuroendocrine tumors of different origin. Specificity of the sst 1 and sst 2A antibodies was confirmed by immunohistochemical identification of approximately 60 and 85 kDa receptor proteins, respectively, in tumors by Western blotting experiments. The high frequency of expression of sst 1 and sst 2A receptor proteins in gastrinomas and carcinoids is in agreement with a predominant expression of sst 1 and sst 2A mRNAs in these tumor types (11) .
The presence and possible functional significance of SSR's and SSR subtypes expressed in normal and tumoral neuroendocrine tissues has been reviewed (2, 10, 12) . While sst 2A and sst 5 are involved in the inhibition of hormone secretion, the functional role of the other SSR subtypes is less clear. In cells transfected with SSR subtype genes, agonist activation of sst 1 , sst 2A , and sst 5 seems involved in the antiproliferative action of SS(-analogs) via distinct as well as overlapping mechanisms (2) . Whether such mechanisms also occur in human tumor cells expressing these particular subtypes remains to be established.
In the present study we found immunoreactive sst 1 primarily in the cytoplasm, whereas sst 2A was predominantly expressed at the cell membrane, irrespective of the tumor type. The membrane-localization of sst 2 is in agreement with a recent study by Janson et al. (13) in human carcinoid tumors. The precise functional significance of our observations is unclear. The cytoplasmic sst 1 may represent either neosynthesized or internalized receptors, as suggested previously to explain the cytoplasmic localization of sst 2A in specific rat brain neurons in regions with high somatostatin expression (14) . However, previous studies with COS or CHO cells transfected with individual SSR subtypes have shown that sst 1 is internalized more poorly than sst 2A after hormone binding (15, 16) . If endogenous receptors in tumors behaved similarly, one would predict that more of the sst 2A than the sst 1 receptor would be internalized in tumors expressing both receptor subtypes. Instead we found the inverse distribution. Moreover, agonist exposure upregulates sst 1 expression in CHO-K1 cells expressing this SSR subtype (16) , while chronic SS exposure of GH 4 C 1 pituitary cells increases SSR numbers (17) . This increase in SSR number in GH 4 C 1 cells was independent of new protein synthesis, and a potential mechanism could be changes in the intracellular distribution of SSRs (17) . In this respect our observation of a predominant cytoplasmic localization of sst 1 receptors in human tumor cells may also reflect a capacity of the tumor cells expressing this SSR subtype to increase SSR numbers after agonist exposure. This suggests that treatment of sst 1 receptor-expressing cells with sst 1 -selective agonists may not result in a desensitization to treatment as has been observed in the majority of patients with islet-cell tumors and carcinoids treated with sst 2 -selective octapeptide SS-analogs (18) . Clearly additional studies will be needed to establish whether this differential localization of sst 1 and sst 2A is a general phenomenon and to determine the biochemical mechanisms responsible.
In summary, the use of SSR subtype specific antibodies now allows a detailed examination of the subcellular localization of SSR subtypes in individual cells. This is an important step toward understanding more about the functional role of the individual SSR subtypes in human SSR positive tumors.
